|
Recruitment of B Positive participants
|
Target population age ≥ 35, HBsAg + ve for ≥ 6 months, born in China, Hong Kong, Vietnam
|
|
Contact testing and immunisation
|
Not factored into the model
|
|
Seroprevalence data in target populations
|
Data provided by Nguyen et al [19]
|
| |
• 10.7% for people born in China
|
| |
• 10.5% for people born in Vietnam
|
| |
• 7.7% for people born in Hong Kong
|
|
Initial testing to confirm CHB
|
Not factored in GP consultation calculations
|
|
Program participation rates
|
Base case assumption is 25% of eligible people enrolled
|
|
Follow up requirements
|
• Routine surveillance arm: 2 GP appointments/year
|
| |
• Enhanced HCC surveillance arm: 2 GP appointments/year
|
| |
• Interferon treatment: 6 specialist appointments/year
|
| |
• Entecavir treatment (includes those with liver failure): 4 specialist appointments/year
|
| |
• Patients with HCC: assumed monthly follow up
|
|
Viral load distribution by age
|
Based upon REVEAL study, [22] as participant profile largely matches that of B Positive participants
|
|
ALT cut-off levels
|
ALT≥ 1.5 × ULN triggers further evaluation in the absence of clinical data; ULN differentiated by participant age
|
|
Progression rates through disease stages
|
Constant over time
|
|
Patients with high VL and abnormal liver function
|
30% receive first line interferon for 12 months
|
| |
• 30% seroconvert and receive no further treatment
|
| |
• 70% commence entecavir the following year
|
| |
70% receive entecavir as first-line treatment
|
| |
• 20% seroconvert in the first year of entecavir treatment and receive no further treatment
|
| |
• 80% continue lifelong entecavir
|
|
Patients with liver failure
|
All receive entecavir
|
